RegeneRx Biopharmaceutica Profile

USD 0.01  5.00%

Conversion by Joseph McNay of 1044560 shares of RegeneRx Biopharmaceutica

RegeneRx Biopharmaceuticals insider trading alert for conversion of convertible promissory note (right to buy) by Joseph McNay, the corporate stakeholder, on April 2, 2018. This event was filed by Regenerx Biopharmaceutica with SEC on 2018-04-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

RegeneRx Biopharmaceutica Summary

RegeneRx Biopharmaceuticals (RGRX) is traded on OTC Market in USA. It is located in 15245 Shady Grove Road and employs 3 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 23.93 M. RegeneRx Biopharmaceuticals has 119.64 M outstanding shares of which 19.19 K shares are at this time shorted by private and institutional investors with about 0.15 trading days to cover. REGENERX BIOPHARM currently holds about 923.5 K in cash with (579.28 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check RegeneRx Biopharmaceutica Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.21HorizonTargetOdds Above 0.21
99.05%30 days 0.21 0.92%
Based on normal probability distribution, the odds of RegeneRx Biopharmaceutica to move above current price in 30 days from now is near 1% (This RegeneRx Biopharmaceuticals probability density function shows the probability of RegeneRx Biopharmaceutica Stock to fall within a particular range of prices over 30 days) .

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Williams Jones Associates LlcCommon Shares150 K33 K
Dumont Blake Investment Advisors LlcCommon Shares22.3 K5 K
View RegeneRx Biopharmaceutica Diagnostics

RegeneRx Biopharmaceutica Risk Profiles

Key Fundamentals

RegeneRx Biopharmaceutica Against Markets

Current Ratings

RegeneRx Biopharmaceutica 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for RegeneRx Biopharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 , for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceutica operates under Biotechnology classification in USA and traded on OTC Market. It employs 3 people. more
NameRegeneRx Biopharmaceuticals
CEO and President and DirectorJ FinkelsteinView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address15245 Shady Grove Road
ExchangeOTC Market
Phone301 208 9191
CurrencyUSD - US Dollar

Current Sentiment - RGRX

RegeneRx Biopharmaceutica Investor Sentiment
Macroaxis portfolio users are evenly split in their perspective on investing in RegeneRx Biopharmaceuticals. What is your perspective on investing in RegeneRx Biopharmaceuticals? Are you bullish or bearish?
50% Bullish
50% Bearish

RegeneRx Biopharmaceutica Corporate Directors

Don Elsey Independent Director
Joseph McNay Independent Director, MBA
Raymond Elsey Independent Director
Additionally take a look at Your Equity Center. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.